CD8A and neoplasm: DCs then process and present tumor antigens derived from the vaccinating cells to the effector T cells (CD4 and CD8) via the formation of antigen–MHC complexes on the DCs, and T cells bind to this complex with their T cell receptors (TCRs) [17,234,235,237].